JP2011105724A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011105724A5 JP2011105724A5 JP2010265465A JP2010265465A JP2011105724A5 JP 2011105724 A5 JP2011105724 A5 JP 2011105724A5 JP 2010265465 A JP2010265465 A JP 2010265465A JP 2010265465 A JP2010265465 A JP 2010265465A JP 2011105724 A5 JP2011105724 A5 JP 2011105724A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- nur
- ligand analog
- ligand
- covalently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003446 ligand Substances 0.000 claims 41
- -1 aminohexanoyl group Chemical group 0.000 claims 18
- 125000000524 functional group Chemical group 0.000 claims 10
- 239000000427 antigen Substances 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 125000004429 atom Chemical group 0.000 claims 7
- 230000007935 neutral effect Effects 0.000 claims 7
- 241000725303 Human immunodeficiency virus Species 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 230000000269 nucleophilic effect Effects 0.000 claims 5
- 102000005962 receptors Human genes 0.000 claims 5
- 108020003175 receptors Proteins 0.000 claims 5
- 102000001301 EGF receptor Human genes 0.000 claims 4
- 108060006698 EGF receptor Proteins 0.000 claims 4
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 claims 4
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 claims 4
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 claims 4
- 102000001690 Factor VIII Human genes 0.000 claims 3
- 108010054218 Factor VIII Proteins 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 229960000301 factor viii Drugs 0.000 claims 3
- 108030001720 Bontoxilysin Proteins 0.000 claims 2
- 241000193155 Clostridium botulinum Species 0.000 claims 2
- 241000193449 Clostridium tetani Species 0.000 claims 2
- 108010053187 Diphtheria Toxin Proteins 0.000 claims 2
- 102000016607 Diphtheria Toxin Human genes 0.000 claims 2
- 108010081690 Pertussis Toxin Proteins 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 claims 2
- 229940053031 botulinum toxin Drugs 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 208000002672 hepatitis B Diseases 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 230000000415 inactivating effect Effects 0.000 claims 2
- 101150006217 lex1 gene Proteins 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000004434 sulfur atom Chemical group 0.000 claims 2
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 231100000765 toxin Toxicity 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims 1
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 102000053602 DNA Human genes 0.000 claims 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 230000001270 agonistic effect Effects 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 125000003172 aldehyde group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000266 alpha-aminoacyl group Chemical group 0.000 claims 1
- 125000003368 amide group Chemical group 0.000 claims 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 1
- 230000003042 antagnostic effect Effects 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 229910052796 boron Inorganic materials 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000005754 cellular signaling Effects 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 125000006165 cyclic alkyl group Chemical group 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 125000006575 electron-withdrawing group Chemical group 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- 125000000468 ketone group Chemical group 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 125000003473 lipid group Chemical group 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 1
- 125000004372 methylthioethyl group Chemical group [H]C([H])([H])SC([H])([H])C([H])([H])* 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- 125000006501 nitrophenyl group Chemical group 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
- 229910052720 vanadium Inorganic materials 0.000 claims 1
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical group [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45729303P | 2003-03-26 | 2003-03-26 | |
| US60/457,293 | 2003-03-26 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006509376A Division JP5503837B2 (ja) | 2003-03-26 | 2004-03-26 | 非共有結合により誘導される求核性タンパク質へのリガンドの共有結合 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011105724A JP2011105724A (ja) | 2011-06-02 |
| JP2011105724A5 true JP2011105724A5 (enExample) | 2011-08-11 |
| JP5827003B2 JP5827003B2 (ja) | 2015-12-02 |
Family
ID=33131674
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006509376A Expired - Fee Related JP5503837B2 (ja) | 2003-03-26 | 2004-03-26 | 非共有結合により誘導される求核性タンパク質へのリガンドの共有結合 |
| JP2010265465A Expired - Fee Related JP5827003B2 (ja) | 2003-03-26 | 2010-11-29 | 非共有結合により誘導される求核性タンパク質へのリガンドの共有結合 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006509376A Expired - Fee Related JP5503837B2 (ja) | 2003-03-26 | 2004-03-26 | 非共有結合により誘導される求核性タンパク質へのリガンドの共有結合 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9006388B2 (enExample) |
| EP (1) | EP1610808A4 (enExample) |
| JP (2) | JP5503837B2 (enExample) |
| CA (1) | CA2520392C (enExample) |
| WO (1) | WO2004087059A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8980646B2 (en) | 2003-03-26 | 2015-03-17 | Sudhir Paul | Proteolytic and covalent antibodies |
| JP5503837B2 (ja) * | 2003-03-26 | 2014-05-28 | ポール，サッドヒル | 非共有結合により誘導される求核性タンパク質へのリガンドの共有結合 |
| WO2004087738A2 (en) | 2003-03-27 | 2004-10-14 | The University Of Texas | Lupus antibodies for passive immunotherapy of hiv/aids |
| BRPI0813948B8 (pt) * | 2007-07-10 | 2021-05-25 | Medy Tox Inc | composição líquida farmacêutica de toxina botulínica com estabilidade melhorada |
| CN105574346A (zh) * | 2008-09-05 | 2016-05-11 | 新基阿维罗米克斯研究公司 | 多肽偶联物与不可逆抑制剂的设计方法和检测方法 |
| NZ598705A (en) | 2009-09-16 | 2014-06-27 | Celgene Avilomics Res Inc | Protein kinase conjugates and inhibitors |
| JP2013516422A (ja) | 2009-12-30 | 2013-05-13 | アビラ セラピューティクス， インコーポレイテッド | タンパク質のリガンド−指向性共有的修飾 |
| EP3511424B1 (en) | 2012-08-03 | 2023-10-18 | University Of Washington Through Its Center For Commercialization | Compositions and methods for improving nanopore sequencing |
| HUE046449T2 (hu) | 2016-09-13 | 2020-03-30 | Allergan Inc | Stabilizált, nem fehérje eredetû, clostridiális toxin készítmények |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5952462A (en) | 1983-11-29 | 1999-09-14 | Igen International Inc. | Transition state analogs |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5695927A (en) | 1988-03-31 | 1997-12-09 | The University Of Arizona, Department Of Internal Medicine, Section Of Hematology And Oncology | Monoclonal antibodies specific for HIV and the hybridomas for production thereof |
| US5445960A (en) | 1988-03-31 | 1995-08-29 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Monoclonal antibodies specific for HIV and hybridomas for their production |
| JP2809533B2 (ja) * | 1991-01-31 | 1998-10-08 | 壽之 松尾 | Ｃｎｐ類似体ペプチド |
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| US5801149A (en) * | 1991-06-19 | 1998-09-01 | Joslin D-Abetes Center, Inc. | Inhibition of signal transduction molecules |
| WO1993015751A1 (en) * | 1992-02-14 | 1993-08-19 | Merck & Co., Inc. | CHIMERIC TOXINS BINDING TO THE GnRH RECEPTOR |
| US5574142A (en) * | 1992-12-15 | 1996-11-12 | Microprobe Corporation | Peptide linkers for improved oligonucleotide delivery |
| US5952307A (en) * | 1994-01-21 | 1999-09-14 | Georgia Tech Research Corp. | Basic α-aminoalkylphosphonate derivatives |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US5543396A (en) * | 1994-04-28 | 1996-08-06 | Georgia Tech Research Corp. | Proline phosphonate derivatives |
| US5916877A (en) * | 1994-10-18 | 1999-06-29 | Georgia Tech Research Corporation | Fluorescent 1-peptidylaminoalkanephosphonate derivatives |
| CN1165344C (zh) | 1995-07-21 | 2004-09-08 | 内布拉斯卡大学评议会 | 用于催化水解HIVgp120的组合物及其制备方法和用途 |
| US6855804B2 (en) | 1998-03-23 | 2005-02-15 | Board Of Regents, The University Of Texas System | Covalently reactive transition state analogs and methods of use thereof |
| US6235714B1 (en) * | 1998-03-23 | 2001-05-22 | Sudhir Paul | Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses |
| EP1085880A2 (en) * | 1998-06-11 | 2001-03-28 | Cerus Corporation | Use of alkylating compounds for inhibiting proliferation of arterial smooth muscle cells |
| WO2001017614A2 (en) * | 1999-09-07 | 2001-03-15 | Conjuchem, Inc. | Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents |
| US6406863B1 (en) | 2000-06-23 | 2002-06-18 | Genetastix Corporation | High throughput generation and screening of fully human antibody repertoire in yeast |
| WO2002079223A2 (en) * | 2001-03-31 | 2002-10-10 | Board Of Regents, The University Of Texas System | Covalently reactive transition state analogs and methods of use thereof |
| JP5503837B2 (ja) * | 2003-03-26 | 2014-05-28 | ポール，サッドヒル | 非共有結合により誘導される求核性タンパク質へのリガンドの共有結合 |
| US8980646B2 (en) | 2003-03-26 | 2015-03-17 | Sudhir Paul | Proteolytic and covalent antibodies |
| WO2004087738A2 (en) | 2003-03-27 | 2004-10-14 | The University Of Texas | Lupus antibodies for passive immunotherapy of hiv/aids |
| EP2091973A4 (en) * | 2006-11-09 | 2010-08-04 | Sudhir Paul | ANTIBODIES TO BINARY EPITOPES AND B-CELL SUPERANTIGEN IMMUNOSTIMULANTS |
| US9969797B2 (en) * | 2008-04-23 | 2018-05-15 | Covalent Bioscience Incorporated | Immunoglobulins directed to bacterial, viral and endogenous polypeptides |
| US20120121633A1 (en) * | 2010-07-16 | 2012-05-17 | Sudhir Paul | Hiv cd4 binding site based covalent immunogen compositions |
-
2004
- 2004-03-26 JP JP2006509376A patent/JP5503837B2/ja not_active Expired - Fee Related
- 2004-03-26 CA CA2520392A patent/CA2520392C/en not_active Expired - Fee Related
- 2004-03-26 EP EP04758449A patent/EP1610808A4/en not_active Ceased
- 2004-03-26 US US10/581,296 patent/US9006388B2/en active Active
- 2004-03-26 WO PCT/US2004/009399 patent/WO2004087059A2/en not_active Ceased
-
2010
- 2010-11-29 JP JP2010265465A patent/JP5827003B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011105724A5 (enExample) | ||
| Yang et al. | Synthesis of multifunctional polymers through the Ugi reaction for protein conjugation | |
| Mogaki et al. | Guanidinium-based “molecular glues” for modulation of biomolecular functions | |
| Pan et al. | Backbone degradable multiblock N-(2-hydroxypropyl) methacrylamide copolymer conjugates via reversible addition− fragmentation chain transfer polymerization and thiol− ene coupling reaction | |
| US11590235B2 (en) | Factor VIII zwitterionic polymer conjugates | |
| JP2012521201A5 (enExample) | ||
| JP2018502131A5 (enExample) | ||
| JP2019172710A5 (enExample) | ||
| JP2018503639A5 (enExample) | ||
| JP2013523896A5 (enExample) | ||
| JP2014516991A5 (enExample) | ||
| JP5472288B2 (ja) | タンパク質の電荷調節剤、及びタンパク質内包高分子ミセル複合体 | |
| CN107660210B (zh) | 基于硼替佐米的递送系统 | |
| JP2011057686A5 (enExample) | ||
| JP2006527762A5 (enExample) | ||
| JP2017512752A5 (enExample) | ||
| RU2012106150A (ru) | Вариантные формы уратоксидазы и их применение | |
| JP2013500304A5 (enExample) | ||
| JP2016535058A5 (enExample) | ||
| CN101759812A (zh) | 一种新型仿穿膜肽结构的壳聚糖衍生物 | |
| RU2015126105A (ru) | Модифицированные суперспиральные белки с улучшенными свойствами | |
| JP2016515999A5 (enExample) | ||
| JP2018531287A5 (enExample) | ||
| Sun et al. | Oxygen carrier based on hemoglobin/poly (L-lysine)-block-poly (L-phenylalanine) vesicles | |
| CN114555607A (zh) | 一类靶向蛋白质水解通路的功能分子及其制备和应用 |